Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Merck registers Phase 2b trial of tulisokibart for noninfectious uveitisOct 9Weekly roundup, 8 itemsglycopyrrolateMerck & Co., Inc.
Sign inSign in